Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Cohort Analysis
33%
Pulmonary Hypertension
33%
Retrospective Study
33%
Lung Infarction
18%
Systemic Mycosis
16%
Mucinosis
16%
Pulmonary Hemorrhage
16%
Inflammatory Bowel Disease
16%
Reactive Oxygen Species
16%
Experimental Arthritis
16%
Intra-Articular Injection
16%
Thromboembolism
16%
Antiphospholipid Antibody
16%
SLEDAI
11%
Lupus Erythematosus
8%
Antiphospholipid Syndrome
8%
Rituximab
7%
Therapeutic Modality
5%
Lung Biopsy
5%
Lung Lavage
5%
Lymphocytopenia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
50%
Lupus Erythematosus Nephritis
18%
Myositis
16%
Retrospective Study
16%
Systemic Mycosis
16%
Lung Hemorrhage
16%
Gout
16%
Mycophenolate Mofetil
16%
Allopurinol
16%
Adverse Event
16%
Reactive Oxygen Metabolite
16%
Experimental Arthritis
16%
Lung Infarction
16%
Bacterial Arthritis
16%
Prospective Cohort Study
16%
Antiphospholipid Antibody
16%
Programmed Death 1 Ligand 1
11%
Disease Activity
8%
Antiphospholipid Syndrome
8%
Kynurenine
8%
Rituximab
7%
Keyphrases
Childhood-onset Systemic Lupus Erythematosus
16%
Systemic Lupus Erythematosus
16%
Lupus Nephritis
16%
Mycophenolate Mofetil
16%
Diffuse Alveolar Hemorrhage
16%
Taiwanese
16%
Invasive Fungal Infection
16%
Survival Impact
16%
Myositis-specific Antibodies
16%
Pulmonary Infarction
16%
Cutaneous Adverse Drug Reactions (cADRs)
16%
Water-soluble Fullerenol
16%
Childhood-onset SLE
13%
Kynurenine
8%
Idiopathic PAH
7%
Pyarthrosis
6%
Erythematous Patches
5%
CD68+ Macrophage
5%
Orphan Receptor
5%
